GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹21 Cr | ₹16 Cr | ₹22 Cr | ₹13 Cr | ₹75 Cr |
What is the latest Contingent Liabilities ratio of GLAND PHARMA ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | ₹21 Cr |
| Mar2024 | ₹16 Cr |
| Mar2023 | ₹22 Cr |
| Mar2022 | ₹13 Cr |
| Mar2021 | ₹75 Cr |
How is Contingent Liabilities of GLAND PHARMA Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹21 Cr | 37.24 | |
| Mar2024 | ₹16 Cr | -29.41 | |
| Mar2023 | ₹22 Cr | 72.94 | |
| Mar2022 | ₹13 Cr | -82.91 | |
| Mar2021 | ₹75 Cr | - | |
Compare Contingent Liabilities of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹40,915.1 Cr | 0.7% | 9.3% | 31.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹464,331.0 Cr | 1.2% | 8.3% | 15.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹181,466.0 Cr | -0.2% | 3% | -0.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹165,952.0 Cr | 1.7% | 9.9% | 46.8% | Stock Analytics | |
| CIPLA | ₹116,229.0 Cr | -2.2% | 4.5% | -4.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,959.0 Cr | -9% | -2.1% | -1.8% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | 0.7% |
9.3% |
31.8% |
| SENSEX | -0.3% |
4.9% |
-7% |
You may also like the below Video Courses